The total return over the past 12 months is +11.33% vs. +16.94% for the S&P 500. So far it's up +165.94% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +11.33% | (28.59%) | (42.42%) | N/A | N/A | N/A |
| Total Return CAGR | +11.33% | (28.59%) | (42.42%) | N/A | N/A | N/A |
| Revenue CAGR | +354.37% | +176.09% | +47.08% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Cue Biopharma, Inc. (CUE)
| Year | Start price | End price | CUE Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $9.16 | $24.36 | +165.94% | +14.51% | +151.43% |
| 2025 | $32.70 | $9.16 | (71.99%) | +17.72% | (89.71%) |
| 2024 | $79.20 | $32.70 | (58.71%) | +24.89% | (83.60%) |
| 2023 | $85.50 | $79.20 | (7.37%) | +26.19% | (33.56%) |
| 2022 | $339.30 | $85.50 | (74.80%) | (18.17%) | (56.63%) |
| 2021 | $375.30 | $339.30 | (9.59%) | +28.74% | (38.33%) |
| 2020 | $476.25 | $375.30 | (21.20%) | +18.37% | (39.57%) |
| 2019 | $141.00 | $476.25 | +237.77% | +31.22% | +206.55% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
